H
Hongyun Biotechnology
Structure-based drug discovery for oncology and rare diseases
About Hongyun Biotechnology
Nanjing Hongyun Biotechnology Co., Ltd. is a clinical-stage biopharmaceutical company founded in 2018. The company leverages a proprietary drug discovery platform centered on structural pharmacology, integrating advanced computational technologies like molecular dynamics, AI, and computational chemistry. This platform aims to overcome drug resistance and address targets with high unmet clinical needs, particularly in oncology and rare diseases. One of the founders, Professor Caihong Yun, previously served as a research scientist at the Dana-Farber Cancer Institute and has extensive experience in structural biology and precision drug design. The CEO is Dr. Maijing Liao.
The company's business model focuses on the research and development of innovative small-molecule drugs. Its core technology facilitates the design of precision therapeutics by understanding the dynamic structures of proteins at an atomic resolution. This approach is intended to significantly improve the efficiency and success rate of new drug development. The company has established R&D centers in Shanghai and Beijing to create a comprehensive system covering structural pharmacology, chemical synthesis, and biological evaluation.
Hongyun Biotechnology's primary product pipeline includes H002, a next-generation EGFR tyrosine kinase inhibitor (TKI). This drug candidate is designed to treat non-small-cell lung carcinoma (NSCLC), specifically targeting resistance to third-generation EGFR inhibitors, such as those with the C797S mutation. As of early 2023, H002 has entered Phase I/IIa clinical trials in both the United States and China. Another pipeline project targeting a novel pathway for breast cancer and other tumors has advanced to the preclinical candidate stage. The company's revenue is primarily generated through venture capital funding, having completed multiple rounds, including a Series B+ round of nearly ¥100 million RMB in May 2023.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2023 | $14M | $55M | Sherpa Venture Partners · Shanghai Renjin Investment Management Center · Fanchuang Capital · Huayin Financial Investment | ↗ |
| SERIES B✓Equity / VC | Jul 2021 | $14M | $55M | Undisclosed | — |
Growth signals
Hongyun Biotechnology's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hongyun Biotechnology in its local ecosystem
The Hongyun Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Sherpa Venture Partners- DCDaYou Capital
- SCShanghai Renjin Investment Management Center
- FCFanchuang Capital
- HIHuayin Financial Investment
- HCHetang Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hongyun Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hongyun Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.